Drug intelligence / Profile preview

teosyal rha deep lines

Development stage: Unknown
Lead developer: Teoxane
Administration: Intradermal, Subcutaneous

Overview

Teosyal RHA Deep Lines (also marketed as Teosyal RHA 3) is an injectable dermal filler composed of cross-linked hyaluronic acid and lidocaine, developed to treat deep dynamic wrinkles and folds such as nasolabial folds, deep lines, and facial creases[1][2][4][6][7]. The product utilizes Resilient Hyaluronic Acid (RHA) technology, designed to mimic natural hyaluronic acid to adapt flexibly to facial movements, preserving skin vitality, softness, and natural expressions while providing volume and support. Lidocaine is included to increase injection comfort. Effects typically last between 9 and 18 months depending on patient and site[1][2].

Brand names: Teosyal RHA Deep Lines
Other names: Teosyal RHA 3RHA 3RHA3RHA-3

Beyond the preview

Go deeper on teosyal rha deep lines.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on teosyal rha deep lines.

Explore the full profile